[8-K] SeaStar Medical Holding Corporation Reports Material Event
SeaStar Medical Holding Corporation disclosed it has resumed an at-the-market equity offering after suspending sales on July 10, 2025. The company previously sold an aggregate of $6.8 million of common stock under the ATM program and had earlier terminated the continuous offering tied to an initial aggregate offering price of $25,000,000. As of August 8, 2025, SeaStar will resume sales under the Company鈥檚 effective Form S-3 for an additional aggregate offering price of $2,166,305. Proceeds, if any, will be used for general corporate purposes, and there is no minimum offering amount so total shares and proceeds are not determinable. Legal opinion and related exhibits are filed with the report.
SeaStar Medical Holding Corporation ha comunicato di aver ripreso un'offerta azionaria at-the-market dopo aver sospeso le vendite il 10 luglio 2025. La societ脿 aveva precedentemente venduto complessivamente $6.8 million di azioni ordinarie nell'ambito del programma ATM e aveva in precedenza terminato l'offerta continua legata a un prezzo iniziale aggregato di $25,000,000. A partire dall'8 agosto 2025, SeaStar riprender脿 le vendite ai sensi del Form S-3 efficace della Societ脿 per un ulteriore prezzo di offerta aggregato di $2,166,305. Gli eventuali proventi saranno utilizzati per scopi aziendali generali; non esistendo un importo minimo d'offerta, il numero totale di azioni e i proventi non sono determinabili. L'opinione legale e gli allegati correlati sono depositati con il rapporto.
SeaStar Medical Holding Corporation inform贸 que ha reanudado una oferta de acciones at-the-market tras suspender las ventas el 10 de julio de 2025. La compa帽铆a hab铆a vendido previamente un total de $6.8 million de acciones ordinarias bajo el programa ATM y hab铆a terminado con anterioridad la oferta continua vinculada a un precio inicial agregado de $25,000,000. A partir del 8 de agosto de 2025, SeaStar reanudar谩 las ventas conforme al Formulario S-3 vigente de la Compa帽铆a por un precio de oferta agregado adicional de $2,166,305. Los ingresos, en su caso, se usar谩n para fines corporativos generales; no existe una cantidad m铆nima de oferta, por lo que el total de acciones y fondos no es determinable. La opini贸n legal y los anexos relacionados se presentan con el informe.
SeaStar Medical Holding Corporation電� 2025雲� 7鞗� 10鞚� 毵り皝鞚� 欷戨嫧頃� 頉� at-the-market 氚╈嫕鞚� 欤检嫕 瓿惦毳� 鞛皽頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 須岇偓電� 鞚挫爠鞐� ATM 頂勲攴鸽灗鞚� 韱淀暣 齑� $6.8 million 靸侂嫻鞚� 氤错喌欤茧ゼ 毵り皝頄堨溂氅�, 齑堦赴 齑� 瓿惦 旮堨暋 $25,000,000鞐� 鞐瓣硠霅� 歆�靻嶌爜 瓿惦電� 旮办〈鞐� 膦呺頄堨姷雼堧嫟. 2025雲� 8鞗� 8鞚茧秬韯� SeaStar電� 須岇偓鞚� 須牓 鞛堧姅 Form S-3鞐� 霐半澕 於旉皜 齑濌车氇暋 $2,166,305 頃滊弰搿� 毵り皝鞚� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 靾橃澋(鞛堧姅 瓴届毎)鞚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅橂┌, 斓滌唽 瓿惦 旮堨暋鞚� 鞐嗢柎 齑� 氚滍枆 欤检嫕 靾橃檧 臁半嫭旮堨暋鞚� 頇曥爼頃� 靾� 鞐嗢姷雼堧嫟. 氩曤 鞚橁铂靹� 氚� 甏�霠� 攵�靻� 靹滊電� 氤搓碃靹滌檧 頃粯 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
SeaStar Medical Holding Corporation a d茅clar茅 avoir repris une offre d'actions at-the-market apr猫s avoir suspendu les ventes le 10 juillet 2025. La soci茅t茅 avait pr茅c茅demment vendu pour un total de $6.8 million d'actions ordinaires dans le cadre du programme ATM et avait auparavant mis fin 脿 l'offre continue li茅e 脿 un prix global initial de $25,000,000. 脌 compter du 8 ao没t 2025, SeaStar reprendra les ventes en vertu du Formulaire S-3 en vigueur de la Soci茅t茅 pour un montant d'offre agr茅g茅 suppl茅mentaire de $2,166,305. Les produits, le cas 茅ch茅ant, seront utilis茅s 脿 des fins g茅n茅rales d'entreprise ; il n'y a pas de montant minimal d'offre, de sorte que le nombre total d'actions et les produits ne peuvent 锚tre d茅termin茅s. L'avis juridique et les annexes connexes sont d茅pos茅s avec le rapport.
SeaStar Medical Holding Corporation gab bekannt, dass sie eine at-the-market-Aktienplatzierung wieder aufgenommen hat, nachdem die Verk盲ufe am 10. Juli 2025 ausgesetzt wurden. Das Unternehmen hatte zuvor insgesamt $6.8 million an Stammaktien im Rahmen des ATM-Programms verkauft und hatte die fortlaufende Platzierung, die an einen anf盲nglichen aggregierten Ausgabepreis von $25,000,000 gebunden war, bereits beendet. Ab dem 8. August 2025 wird SeaStar die Verk盲ufe gem盲脽 dem wirksamen Form S-3 des Unternehmens f眉r einen zus盲tzlichen aggregierten Ausgabepreis von $2,166,305 wieder aufnehmen. Erl枚se, falls vorhanden, werden f眉r allgemeine Unternehmenszwecke verwendet; da kein Mindestangebotsbetrag besteht, sind die Gesamtanzahl der Aktien und die Erl枚se nicht bestimmbar. Die rechtliche Stellungnahme und zugeh枚rige Anh盲nge sind dem Bericht beigef眉gt.
- Resumption of ATM offering restores an available channel to raise equity capital under the company鈥檚 effective Form S-3
- $6.8 million in common stock has already been sold under the ATM, demonstrating prior market-access execution
- Initial $25.0 million continuous offering was terminated, leaving a smaller immediate capacity than originally planned
- Additional available capacity is limited to $2,166,305, which is modest relative to prior aggregate targets
- No minimum offering amount means total shares and proceeds are indeterminate, creating execution uncertainty
Insights
TL;DR: Resumption of a modest ATM after prior suspension raises near-term financing optionality but does not materially change capital structure.
The company鈥檚 decision to resume sales under its at-the-market program restores an available channel to raise equity capital, following a pause on July 10, 2025. Having already sold $6.8 million, the newly authorized additional capacity of $2,166,305 is limited relative to the originally-terminated $25.0 million initial program, indicating a smaller immediate funding window. Because the filing states there is no minimum offering amount and proceeds are not determinable, the disclosure is routine and mainly affects liquidity flexibility rather than providing a material change to operating metrics.
TL;DR: Routine capital markets disclosure: ATM resumed under an effective S-3, provides optionality but uncertainty on timing and amount of proceeds.
Resuming sales under an effective Form S-3 preserves the company鈥檚 ability to access equity markets via an ATM offering. The filing confirms regulatory readiness by referencing the shelf registration declared effective December 22, 2023 and attaches counsel opinion. The limited additional aggregate offering price of $2,166,305 suggests a targeted, modest raise if executed; absence of a minimum and indeterminate total proceeds means investor impact depends entirely on actual execution, not this disclosure alone.
SeaStar Medical Holding Corporation ha comunicato di aver ripreso un'offerta azionaria at-the-market dopo aver sospeso le vendite il 10 luglio 2025. La societ脿 aveva precedentemente venduto complessivamente $6.8 million di azioni ordinarie nell'ambito del programma ATM e aveva in precedenza terminato l'offerta continua legata a un prezzo iniziale aggregato di $25,000,000. A partire dall'8 agosto 2025, SeaStar riprender脿 le vendite ai sensi del Form S-3 efficace della Societ脿 per un ulteriore prezzo di offerta aggregato di $2,166,305. Gli eventuali proventi saranno utilizzati per scopi aziendali generali; non esistendo un importo minimo d'offerta, il numero totale di azioni e i proventi non sono determinabili. L'opinione legale e gli allegati correlati sono depositati con il rapporto.
SeaStar Medical Holding Corporation inform贸 que ha reanudado una oferta de acciones at-the-market tras suspender las ventas el 10 de julio de 2025. La compa帽铆a hab铆a vendido previamente un total de $6.8 million de acciones ordinarias bajo el programa ATM y hab铆a terminado con anterioridad la oferta continua vinculada a un precio inicial agregado de $25,000,000. A partir del 8 de agosto de 2025, SeaStar reanudar谩 las ventas conforme al Formulario S-3 vigente de la Compa帽铆a por un precio de oferta agregado adicional de $2,166,305. Los ingresos, en su caso, se usar谩n para fines corporativos generales; no existe una cantidad m铆nima de oferta, por lo que el total de acciones y fondos no es determinable. La opini贸n legal y los anexos relacionados se presentan con el informe.
SeaStar Medical Holding Corporation電� 2025雲� 7鞗� 10鞚� 毵り皝鞚� 欷戨嫧頃� 頉� at-the-market 氚╈嫕鞚� 欤检嫕 瓿惦毳� 鞛皽頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 須岇偓電� 鞚挫爠鞐� ATM 頂勲攴鸽灗鞚� 韱淀暣 齑� $6.8 million 靸侂嫻鞚� 氤错喌欤茧ゼ 毵り皝頄堨溂氅�, 齑堦赴 齑� 瓿惦 旮堨暋 $25,000,000鞐� 鞐瓣硠霅� 歆�靻嶌爜 瓿惦電� 旮办〈鞐� 膦呺頄堨姷雼堧嫟. 2025雲� 8鞗� 8鞚茧秬韯� SeaStar電� 須岇偓鞚� 須牓 鞛堧姅 Form S-3鞐� 霐半澕 於旉皜 齑濌车氇暋 $2,166,305 頃滊弰搿� 毵り皝鞚� 鞛皽頃� 鞓堨爼鞛呺媹雼�. 靾橃澋(鞛堧姅 瓴届毎)鞚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅橂┌, 斓滌唽 瓿惦 旮堨暋鞚� 鞐嗢柎 齑� 氚滍枆 欤检嫕 靾橃檧 臁半嫭旮堨暋鞚� 頇曥爼頃� 靾� 鞐嗢姷雼堧嫟. 氩曤 鞚橁铂靹� 氚� 甏�霠� 攵�靻� 靹滊電� 氤搓碃靹滌檧 頃粯 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
SeaStar Medical Holding Corporation a d茅clar茅 avoir repris une offre d'actions at-the-market apr猫s avoir suspendu les ventes le 10 juillet 2025. La soci茅t茅 avait pr茅c茅demment vendu pour un total de $6.8 million d'actions ordinaires dans le cadre du programme ATM et avait auparavant mis fin 脿 l'offre continue li茅e 脿 un prix global initial de $25,000,000. 脌 compter du 8 ao没t 2025, SeaStar reprendra les ventes en vertu du Formulaire S-3 en vigueur de la Soci茅t茅 pour un montant d'offre agr茅g茅 suppl茅mentaire de $2,166,305. Les produits, le cas 茅ch茅ant, seront utilis茅s 脿 des fins g茅n茅rales d'entreprise ; il n'y a pas de montant minimal d'offre, de sorte que le nombre total d'actions et les produits ne peuvent 锚tre d茅termin茅s. L'avis juridique et les annexes connexes sont d茅pos茅s avec le rapport.
SeaStar Medical Holding Corporation gab bekannt, dass sie eine at-the-market-Aktienplatzierung wieder aufgenommen hat, nachdem die Verk盲ufe am 10. Juli 2025 ausgesetzt wurden. Das Unternehmen hatte zuvor insgesamt $6.8 million an Stammaktien im Rahmen des ATM-Programms verkauft und hatte die fortlaufende Platzierung, die an einen anf盲nglichen aggregierten Ausgabepreis von $25,000,000 gebunden war, bereits beendet. Ab dem 8. August 2025 wird SeaStar die Verk盲ufe gem盲脽 dem wirksamen Form S-3 des Unternehmens f眉r einen zus盲tzlichen aggregierten Ausgabepreis von $2,166,305 wieder aufnehmen. Erl枚se, falls vorhanden, werden f眉r allgemeine Unternehmenszwecke verwendet; da kein Mindestangebotsbetrag besteht, sind die Gesamtanzahl der Aktien und die Erl枚se nicht bestimmbar. Die rechtliche Stellungnahme und zugeh枚rige Anh盲nge sind dem Bericht beigef眉gt.
FAQ
What did SeaStar Medical (ICU) disclose in this Form 8-K?
How much has SeaStar sold previously under the ATM?
How much additional offering capacity did SeaStar authorize?
Will SeaStar Medical receive a minimum amount from the ATM offering?
What will SeaStar use any net proceeds for?
